SCHEMBL17519154

SCHEMBL17519154

Cc1cccc(C(N)C(N)c2ccc(Cl)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.45
CYP3A4 P08684 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A3 Q01959 2/20 0.42
OPRM1 P35372 2/20 0.42
OPRK1 P41145 2/20 0.42
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
HPN P05981 1/20 0.42
CHRM2 P08172 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42
DRD2 P14416 1/20 0.42
ADRA2C P18825 1/20 0.42
CNR1 P21554 1/20 0.42
DRD1 P21728 1/20 0.42
DRD4 P21917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15952076 0.86 HTR2A (0.40) ADRB2CYP3A4SLC6A2SLC6A3OPRM1
SCHEMBL19598016 0.86 HTR2A (0.40) ADRB2CYP3A4SLC6A2SLC6A3OPRM1
SCHEMBL12569050 0.86 ACHE (0.52) DPP4MAPK1ACHEIDO1AOC3
SCHEMBL3254719 0.86 ACHE (0.52) DPP4MAPK1ACHEIDO1AOC3
SCHEMBL3259002 0.86 ACHE (0.52) DPP4MAPK1ACHEIDO1AOC3
SCHEMBL17519156 0.82 OPRM1 (0.49) ADRB2OPRM1OPRK1DPP4IDO1
SCHEMBL19619720 0.79 SLC6A4 (0.44) SLC6A2SLC6A3SLC6A4DPP4KMT2A
SCHEMBL23428902 0.78 CYP3A4 (0.42) CYP3A4SLC6A2SLC6A3OPRM1OPRK1
SCHEMBL17519152 0.78 OPRL1 (0.43) ADRB2OPRM1OPRK1DPP4IDO1
SCHEMBL17519158 0.77 CASR (0.41) HTR2AHTR2BDPP4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647702-B2 Aryl-substituted imidazoles ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2020-05-12 US disclosed
US-20190345141-A1 ARYL-SUBSTITUTED IMIDAZOLES ST JUDE CHILDRENS RES HOSPITAL (US) 2019-11-14 US disclosed
EP-2621275-B1 ARYL-SUBSTITUTED IMIDAZOLES ST JUDE CHILDRENS RES HOSPITAL (US) 2018-03-28 EP disclosed
US-9822100-B2 Aryl-substituted imidazoles ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-11-21 US disclosed
US-20160297800-A1 ARYL-SUBSTITUTED IMIDAZOLES ST JUDE CHILDREN'S RES HOSPITAL (US) 2016-10-13 US disclosed
US-9266860-B2 Aryl-substituted imidazoles ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2016-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345141-A1 ARYL-SUBSTITUTED IMIDAZOLES MDM2, TP53, MDM4 ADRB2 4051/4885CYP3A4 1488/4885SLC6A2 4334/4885
US-10647702-B2 Aryl-substituted imidazoles MDM2, TP53, MDM4 ADRB2 4051/4885CYP3A4 1488/4885SLC6A2 4334/4885
US-20160297800-A1 ARYL-SUBSTITUTED IMIDAZOLES MDM2, TP53, MDM4 ADRB2 4051/4885CYP3A4 1488/4885SLC6A2 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.